OPUS GENETICS, INC.

Profile

Company Names

OPUS GENETICS, INC.
OCUPHIRE PHARMA, INC.

Addresses

37000 GRAND RIVER AVENUE, SUITE 120, FARMINGTON HILLS, MI 48335

37000 GRAND RIVER AVE., SUITE 120, FARMINGTON HILLS, MI 48335

Phone Numbers

1 (248) 957-9024
248-681-9815

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$46,928,641.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2024-10-22 
$25,778,641.00 
$25,778,641.00 
$0.00 
Equity 
1
2020-11-05 
$21,150,000.00 
$21,150,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SEAN 
 
AINSWORTH 
DIRECTOR
RETROSENSE THERAPEUTICS, LLC   |  IMMUSOFT CORP   |  OCUPHIRE PHARMA, INC.   |  OCUPHIRE PHARMA, INC.   |  RAY THERAPEUTICS, INC.   |  OPUS GENETICS, INC.
DR. JEAN 
 
BENNETT 
DIRECTOR
OPUS GENETICS, INC.
SUSAN 
 
BENTON 
DIRECTOR
SIRION HOLDINGS, INC.   |  SIRION HOLDINGS, INC.   |  OPUS GENETICS, INC.
SUSAN 
K. 
BENTON 
DIRECTOR
OCUPHIRE PHARMA, INC.
CAM 
 
GALLAGHER 
DIRECTOR
NERVEDA INC   |  NERVEDA LLC   |  SORRENTO THERAPEUTICS, INC.   |  KALYRA PHARMACEUTICALS, INC.   |  SG PHARMACEUTICALS, INC.   |  RETROSENSE THERAPEUTICS, LLC   |  ZAVANTE THERAPEUTICS, INC.   |  ZENO PHARMACEUTICALS, INC.   |  ONCTERNAL THERAPEUTICS, INC.   |  VELOSBIO INC.   |  OCUPHIRE PHARMA, INC.   |  OCUPHIRE PHARMA, INC.   |  SELECTION, INC.   |  OPUS GENETICS, INC.   |  ALESSA THERAPEUTICS, INC.
DR. ADRIENNE 
 
GRAVES 
DIRECTOR
OPUS GENETICS, INC.
BERNHARD 
 
HOFFMANN 
EXECUTIVE OFFICER
OCUPHIRE PHARMA, INC.   |  OCUPHIRE PHARMA, INC.   |  OPUS GENETICS, INC.
ASH 
 
JAYAGOPAL 
EXECUTIVE OFFICER
OPUS GENETICS, INC.
NIRAV 
 
JHAVERI 
EXECUTIVE OFFICER
OPUS GENETICS, INC.
DR. GEORGE 
 
MAGRATH 
DIRECTOR, EXECUTIVE OFFICER
OPUS GENETICS, INC.
JAMES 
 
MANUSO 
DIRECTOR
OCUPHIRE PHARMA, INC.   |  TUHURA BIOSCIENCES, INC.   |  OPUS GENETICS, INC.   |  TUHURA BIOSCIENCES, INC./NV
JAMES 
S. 
MANUSO 
DIRECTOR
NOVELOS THERAPEUTICS, INC.   |  RESPIRERX PHARMACEUTICALS INC.   |  OCUPHIRE PHARMA, INC.
ALAN 
R. 
MEYER 
DIRECTOR
OCUPHIRE PHARMA, INC.
AMY 
 
RABOURN 
EXECUTIVE OFFICER
OPUS GENETICS, INC.
RICHARD 
 
RODGERS 
DIRECTOR
LOSO, INC.   |  FOUNDATIONS RECOVERY NETWORK LLC   |  3-V BIOSCIENCES, INC.   |  ARDELYX, INC.   |  SAGIMET BIOSCIENCES INC.   |  OPUS GENETICS, INC.
RICHARD 
J. 
RODGERS 
DIRECTOR
TESARO, INC.   |  OCUPHIRE PHARMA, INC.
JOSEPH 
 
SCHACHLE 
EXECUTIVE OFFICER
OPUS GENETICS, INC.
MINA 
 
SOOCH 
EXECUTIVE OFFICER, DIRECTOR
PRONAI THERAPEUTICS INC   |  SVELTE MEDICAL SYSTEMS INC   |  GEMPHIRE THERAPEUTICS INC.   |  OCUPHIRE PHARMA, INC.   |  BIOVIE INC.   |  OCUPHIRE PHARMA, INC.
DR. BENJAMIN 
 
YERXA 
DIRECTOR, EXECUTIVE OFFICER
OPUS GENETICS, INC.
AMY 
 
ZAREMBA RABOURN 
EXECUTIVE OFFICER
GEMPHIRE THERAPEUTICS INC.   |  OCUPHIRE PHARMA, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-11-07
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2024-10-22 
2020-11-20
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2020-11-05 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
CANTOR FITZGERALD + CO.
134
CANACCORD GENUITY CORP.
NONE
CANACCORD GENUITY LLC
1020